Hematopoietic stem cell transplantation infections

Leather HL, Wingard JR. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am 2001 15 483-520. [Pg.2215]

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for SCD. The best candidates are children with SCD who are younger than 16 years of age with severe complications who have an identical H LA-matched donor, usually a sibling. The transplant-related mortality rate is between 5% and 10%, and graft rejection is approximately 10%. Other risks include secondary malignancies, development of seizures or intracranial bleeding, and infection in the immediate posttransplant period.6,25,32,33... [Pg.1014]

Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000 49 1-125, CE1-7. [Pg.1465]

For the treatment of patients with esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT). [Pg.1694]

Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogenic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003 102 827-33. [Pg.65]

Tanaka Y, Kanda Y, Kami M, Mori S, Hamaki T, Kusumi E, et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002 30 315-9. [Pg.1586]

INFECTIONS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)... [Pg.2206]

Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation practice guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001 392 21. [Pg.2213]

Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000 49(RR-10) 1-110. [Pg.2215]

Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation a matched control study. Biol Blood Marrow Transplant 2002 8 512-520. [Pg.2557]

Boeckh M, Berrey MM, Bowden RA et al. (2001). Phase I evaluation of the RSV-specihc humanised monoclonal antibody pahvizumab in hematopoietic stem cell transplant recipients. J Infect Dis, 184, 350-354. [Pg.463]

Micafungin sodium is an antifungal agent that inhibits synthesis of 1,3-B-D-glucan, an essential component of fungal cell walls, but not present in mammalian cells. It is indicated in the treatment of esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem-cell transplantation. [Pg.441]

Asakura M, Ikegame K, Yoshihara S, Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol 2010 92(2) 351-9. [Pg.468]

Kanda Y. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 2010 12(5) 421-7. [Pg.469]

Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, Kim HJ, Cho SG, Eom KS, Lee JW, Min WS, Shin WS, Kim CC. Infectious comphcations associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation comparison with anti-thymocyte globuhn. Transpl Infect Dis 2009 11(5) 413-23. [Pg.600]

Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdiere M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009 11 89-93. [Pg.565]

Kim C-C. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation comparison with anti-thymocyte globulin. Transplant Infect Dis 2009 11 413-23. [Pg.803]

Mossad S, Kalaycio M, Sobecks R, et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005 35(4) 375 81. [Pg.570]

Bacigalupo A, Boyd A, Slipper J, Curtis J, Clissold S. Foscamet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther 2012 10(ll) 1249-64. [Pg.432]

Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, et al. Initial low-dose valganddovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2012 96(1) 94—100. [Pg.433]

Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M (2003) Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 36 1139-1143... [Pg.208]

Navari RM, Sullivan KM, Springmeyer SC, Siegel MS, Meyers JD, Buckner CD, Sanders JE, Stewart PS, Clift RA, Fefer A et al (1983) Mycobacterial infections in marrow transplant patients. Transplantation 36 509-513 Nichols WG, Corey L, Gooley T, Davis C, Boeckh M (2001) Parainfluenza virus infections after hematopoietic stem cell transplantation risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98 573-578... [Pg.209]

Nichols WG, Guthrie KA, Corey L, Boeckh M (2004) Influenza infections after hematopoietic stem cell transplantation risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39 1300-1306 Nusair S, Breuer R, Shapira MY, Berkman N, Or R (2004) Low incidence of pulmonary complications following nonmyeloablative stem cell transplantation. Eur Respir J 23 440-445... [Pg.209]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...